Canadian biotech Nanostics has been awarded a C$3.8 million grant from Genome Canada and Genome Alberta to accelerate adoption of its ClarityDx Prostate test, which leverages machine learning to evaluate prostate cancer aggressiveness via blood biomarkers and clinical features. The funding supports studies to demonstrate clinical utility, health impact, and healthcare integration, aimed at gaining insurance reimbursement and standard-of-care status in Canada. The company is also commercializing the test in the US and Middle East and has CE-IVD marking since 2022.